Previous Close | 4.9500 |
Open | 4.9500 |
Bid | 4.4000 |
Ask | 4.7500 |
Strike | 32.00 |
Expire Date | 2025-06-20 |
Day's Range | 4.9500 - 5.0200 |
Contract Range | N/A |
Volume | |
Open Interest | 4.35k |
NEW YORK, June 03, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 11:20 a.m. Eastern Daylight Time.
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
NEW YORK, June 01, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0